Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523753 | 0.84 | LTA4H (1.00) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30642394 | 0.84 | LTA4H (1.00) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL19197927 | 0.83 | RAB9A (0.71) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30520525 | 0.83 | RAB9A (0.71) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL10371775 | 0.83 | LTA4H (0.72) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6710546 | 0.83 | LTA4H (0.72) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL10561769 | 0.83 | LTA4H (0.72) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6730573 | 0.83 | LTA4H (0.72) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL171745 | 0.83 | ALDH1A1 (1.00) | LTA4HALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL25547422 | 0.83 | LTA4H (0.72) | LTA4HALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015040425-A1 | RESORCINOL N-ARYL AMIDE COMPOUNDS, FOR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015040425-A1 | RESORCINOL N-ARYL AMIDE COMPOUNDS, FOR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-03-26 | — | — | WO | disclosed |
| EP-1840121-B1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2042171-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2033637-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | TORAY INDUSTRIES (JP) | 2011-02-09 | — | — | EP | disclosed |
| EP-2033637-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | Toray Industries, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-1840121-A1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | LTA4H 1721/4885ALDH1A1 1187/4885MEN1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.